Compare DXLG & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXLG | BYSI |
|---|---|---|
| Founded | 1976 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 31.4M |
| IPO Year | 1994 | 2016 |
| Metric | DXLG | BYSI |
|---|---|---|
| Price | $0.52 | $0.47 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.13 | N/A |
| AVG Volume (30 Days) | 132.2K | ★ 282.5K |
| Earning Date | 12-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $435,017,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.48 | $49.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $0.47 |
| 52 Week High | $1.58 | $2.44 |
| Indicator | DXLG | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 32.91 |
| Support Level | $0.46 | N/A |
| Resistance Level | $0.59 | $0.80 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 83.14 | 6.99 |
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.